Zuo, Bingfeng et al. painted DEVs with hepatocellular carcinoma peptides, α-fetoprotein epitope and an immunoadjuvant (which was nucleosome-binding protein 1) to promote the recruitment and activation of DCs in tumor sites, achieving the cross-presentation of tumor neoantigens and causing tumor eradication [81]. Here, HMGN5 is linked to hepatocellular carcinoma.